Investigational drug · Phase 2
APG-115
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma, Liposarcoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
10
Any phase or sponsor naming "APG-115"
First trial start
2018
Aug 29, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "APG-115", any sponsor or status.
Conditions studied
As listed on its trial records.
- T-Prolymphocytic Leukemia
- Non-Hodgkins Lymphoma
- Liposarcoma
- Advanced Solid Tumor
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors
- Melanoma
- Uveal Melanoma
- P53 Mutation
- MDM2 Gene Mutation
- Cutaneous Melanoma
Approved drugs for the same conditions: Melanoma · Sarcoma · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "APG-115" as an intervention, largest first.
- A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsActive, not recruiting
Ascentage Pharma Group Inc.Industry
NCT03611868 · 230 participants (planned) · Start Aug 29, 2018 · Primary completion Dec 30, 2025
Drug: Phase 1b: APG-115+pembrolizumab · For: Unresectable or Metastatic Melanoma or Advanced Solid Tumors; Melanoma; Uveal Melanoma and 5 more
Sites: Tucson, Arizona; Rogers, Arkansas; Los Angeles, California · 21 sites in all
- A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Status unknown
Ascentage Pharma Group Inc.Industry
NCT04275518 · 102 participants (planned) · Start Jul 6, 2020 · Primary completion Dec 31, 2025
Drug: APG-115; Azacitidine and 1 more · For: Acute Myeloid Leukemia (AML); Myelodysplastic Syndromes (MDS)
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 14 sites in all
Ascentage Pharma Group Inc.Industry
NCT05701306 · 100 participants (planned) · Start Feb 28, 2023 · Primary completion Jun 1, 2027
Drug: APG-115; APG-2575 · For: Neuroblastoma; Solid Tumor
Sites: Guangzhou, China; Wuhan, China; Tianjin, China
Ascentage Pharma Group Inc.Industry
NCT04785196 · 95 participants (planned) · Start May 26, 2021 · Primary completion Apr 2026
Drug: APG-115; Toripalimab · For: Liposarcoma; Advanced Solid Tumor
Sites: Guangzhou, China; Hangzhou, China; Shanghai, China
Ascentage Pharma Group Inc.Industry
NCT04496349 · 78 participants (planned) · Start Jul 12, 2021 · Primary completion May 31, 2026
Drug: APG-115; APG-2575 · For: T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma
Sites: Houston, Texas
- A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDSStatus unknown
Ascentage Pharma Group Inc.Industry
NCT04358393 · 69 participants (planned) · Start Dec 4, 2020 · Primary completion Dec 30, 2024
Drug: APG-115; 5-azacitidine · For: AML; Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia and 4 more
Sites: Gilbert, Arizona; Denver, Colorado; Durham, North Carolina · 8 sites in all
Ascentage Pharma Group Inc.Industry
NCT02935907 · 50 participants · Start Oct 2016 · Primary completion Jun 28, 2019
Drug: APG-115 · For: Patients With Advanced Solid Tumor or Lymphoma
Sites: Grand Rapids, Michigan; San Antonio, Texas
AeRang KimAcademic, hospital or other
NCT06735820 · 45 participants (planned) · Start Jun 1, 2026 · Primary completion Oct 1, 2027
Drug: APG-115; Selumetinib · For: Malignant Peripheral Nerve Sheath Tumor (MPNST); Neurofibromatosis 1 (NF1); Atypical Neurofibroma
Sites: Washington D.C., District of Columbia; Dallas, Texas
- APG-115 in Salivary Gland Cancer TrialActive, not recruiting
University of Michigan Rogel Cancer CenterAcademic, hospital or other
NCT03781986 · 41 participants · Start Oct 28, 2019 · Primary completion Jan 19, 2026
Drug: APG-115; Carboplatin · For: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Sites: Tampa, Florida; Chicago, Illinois; Ann Arbor, Michigan
National Cancer Institute (NCI)NIH
NCT06654050 · 0 participants · Start Mar 16, 2026 · Primary completion Mar 16, 2026
Drug: alrizomadlin · For: Mesothelioma; Malignant Mesothelioma (MM); Early-stage Mesothelioma and 3 more
Sites: Bethesda, Maryland
Newest research
PubMed records naming it or its code names, newest first.
- TRIM22-mediated ubiquitin-dependent degradation of FLT3-ITD overcomes TKI resistance in acute myeloid leukemia.
Liu M, Wang X, He X, et al. · Life Med 2026
- MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial.
Pearson AT, Muzaffar J, Kirtane K, et al. · Nat Commun 2026
- The MDM2-p53 Axis in Osteosarcoma: Current Understanding of Regulatory Mechanisms and Targeted Therapeutic Strategies.
Deng W, Gao S, Yan L, et al. · Pharmaceuticals (Basel) 2026
- Magnet-Responsive Nanomaterials Trigger Ferroptosis and Cellular Senescence Modulation via p53/SLC7A11 Axis for Tumor Therapy.
Wang X, Zhang M, Jiang H, et al. · Adv Healthc Mater 2026
- Novel antagonist APG-115 targets MDM2-p53 to induce p53-mediated apoptosis and radiosensitization in colorectal cancer.
Yi H, Han Y, Wang X, et al. · Clin Exp Med 2026
- APG-115 synergizes with bortezomib to induce apoptosis in cervical cancer cells.
Sun C, Meng X, Cui X, et al. · Anticancer Drugs 2025
Also in development for T-Prolymphocytic Leukemia
- APG-2575lisaftoclaxPhase 310 trials
Ascentage Pharma Group Inc. · CLL/SLL, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.